Live event and webcast TODAY at 10 a.m. ET
Saint Herblain (France), October 10, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an investor day today in New York City to discuss the Company’s key value drivers over the next 12-18 months and beyond after that. Valneva Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company’s senior management team highlight the Company’s substantial opportunity for its partner-led Lyme disease vaccine candidate Pfizer, Valneva’s growing commercial vaccine business, and opportunities for continued value. creation from the Company’s promising R&D pipeline.
Shows begin today at 10 a.m. ET (4:00 p.m. CET) and will be available in the Presentation section from the Valneva website. The event will also be webcast live and archived on the Events page in the Share investors from the Valneva website. The meeting will be held in a hybrid way – in person and webcast. To register, click here. There will be two Q&A sessions during and immediately after the formal presentations with the opportunity for virtual attendees to participate.
Valneva will emphasize the following:
- VLA15, its vaccine candidate against Lyme disease, which is currently fully enrolled with a primary vaccine series completed in a pivotal Phase 3 study led by Pfizer
- The Company’s commercial portfolio of passenger vaccines, including the ongoing launch of IXCHIQ® against chikungunya virus
- The Company’s clinical and preclinical R&D pipeline, which includes ongoing clinical development for IXCHIQ® (Phase 4 and other studies), SV4 against Shigella in Phase 2, and VLA1601 against Zika virus in Phase 1. Valneva will also discuss further development of the R&D pipeline and selected existing targets.
- There will also be a brief financial overview highlighting 2024 and mid-term guidance.
Thomas Lingelbach, CEO of Valneva“This is a very important moment for Valneva as we approach the third and final second season before the Phase 3 trial of our Lyme disease vaccine, VLA15, ends next year. If accepted and commercialized by our partner Pfizer, we believe we can achieve sustainable profitability from 2027, also supported by the revenue growth we expect from the travel vaccines portfolio that we already have over the coming years, including the global launch and adoption of IXCHIQ®. We are committed to continuing to invest in developing different vaccines in unmet medical needs – in line with our vision to contribute to a world where no one dies or ‘suffer from a vaccine-preventable disease.”
There is information about Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, leveraging our in-depth knowledge across multiple vaccine modalities, with a focus on providing first-in-class, first-in-class or next-generation vaccine solutions. type only.
We have a strong track record of advancing multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine , as well as some third-party vaccines.
Revenue from our growing commercial business helps advance the continued progress of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most advanced Shigella vaccine candidate, as well as antiviral vaccine candidates Zika and other global public health threats. More information is available at www.valneva.com.
Forward looking statements
This press release contains certain forward-looking statements relating to Valneva’s business, including: 2024 financial results; medium term income and cash outlook; the progress, timing, results and completion of research, development and clinical trials for product candidates; request regulatory approval for product candidates and labeling extensions; and review of existing products. In addition, even if Valneva’s actual results or development are consistent with the forward-looking statements in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements with words such as “may,” “should,” “may,” “expect,” “expect,” “believe, ” “expects,” “estimates,” “goals,” “targets,” or similar words. These forward-looking statements are based largely on Valneva’s expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that could affect actual results. , materially cause a performance or performances. differ from any future results, performance or performance expressed or implied by these forward-looking statements. In particular, Valneva’s prospects could be affected by, among other things, uncertainties and delays in the development and production of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in the general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. Due to these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will be realized. Valneva provides this information as of the date of this press release and disclaims any intention or obligation to update or revise any future statements, whether as a result of new information, future or other events.
2024-10-10 05:02:00
#Valneva #hosts #Investor #Day #York #City
